imc-002
mAbexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2020 (NCT04306224)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06557174 | Phase 1/Phase 2 (Phase 2) | Oct 10, 2024 | Government of China |
| NCT06535412 | Phase 1/Phase 2 (Phase 2) | Oct 10, 2024 | Government of China |
| NCT05946226 | Phase 1 | Sep 7, 2023 | Government of China, People's Liberation Army of China |
| NCT05276310 | Phase 1 | May 10, 2022 | ImmuneOncia Therapeutics Inc. |
| NCT04306224 | Phase 1 | May 31, 2020 | ImmuneOncia Therapeutics Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 3 | 2 | 2023 |
| ImmuneOncia Therapeutics Inc. | For profit | 2 | 2 | 1 | 2020 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1